Figure 11: Anti-arteriosclerosis Effect (ii) Anatomical Findings
FIGURE 12
Figure 12: Inhibition of Hyaluronidase Activity by Es A/Esg-A/Es B/Esg-B/Cromo with a Modified Morgan-Elson Method.
The grey dash line shows 50% inhibition on hyaluronidase activity. Each value was the average of triplicates, and each bar indicates the mean ± SEM (n=5). Es A, Esculeoside A; Esg A, Esculeogenin A; Es B, Esculeoside B; Esg B, Esculeogenin B; Cromo,
cromoglycate.
FIGURE 13
Figure 13: Oral administration of Es A or Es B on the Amelioration of Experimental Dermatitis in DNCB-treated Mice for the Care and Use of Laboratory Animals. The mice were divided into 6 (Es A) or 3 (Es B) groups. Saline application was as
the normal. Saline administration after atopic dermatitis induction was as the control. Dexa (0.1 mg/kg) and Es A (10, 50 and
100 mg/kg) or Es B (10 mg/kg) administration after atopic dermatitis induction were as the treatment groups. b. Macroscopic
photograph after 4 weeks oral administration. Dermatitis scores were assessed macroscopically in a blinded fashion during a 4-
week period. c. Histopathological findings of mice dorsal skin were at 4-week after various application following atopic dermatitis induction. H&E staining, ×100. The results were expressed as means ± SEM. (n=3~6). *: P < 0.05, ***: P < 0.001, significantly different from the Control. Es A, Esculeoside A; Es B, Esculeoside B; Dexa, dexamethasone.
FIGURE 14
Figure 14: Effectiveness of Steroid Glycosides such as Tomato Saponin (Esculeoside A)
Figures at a glance